AU Patent

AU2009313879B2 — Ingestible therapy activator system and method

Assigned to Proteus Digital Health Inc · Expires 2011-10-20 · 15y expired

What this patent protects

An ingestible therapy activator system and method are provided. In one aspect, the ingestible therapy activator includes an ingestible device having an effector module to send an effector instruction and a responder module associated with a therapeutic device. The responder modul…

USPTO Abstract

An ingestible therapy activator system and method are provided. In one aspect, the ingestible therapy activator includes an ingestible device having an effector module to send an effector instruction and a responder module associated with a therapeutic device. The responder module may receive and process the effector instruction, resulting in a response by the therapeutic device. Examples of responses by therapeutic device include activating a therapy, deactivating a therapy, modulating a therapy, and discontinuing a therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2009313879B2
Jurisdiction
AU
Classification
—
Expires
2011-10-20
Drug substance claim
No
Drug product claim
No
Assignee
Proteus Digital Health Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.